View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Philips unveils latest CT and MR innovations in radiation therapy, adv...

Philips unveils latest CT and MR innovations in radiation therapy, advancing precision cancer care at ASTRO 2025 September 26, 2025 New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term valuePhilips debuts helium-free [2] BlueSeal RT 1.5T 70cm MR system with AI-powered SmartSpeed Precise, expanding its leadership in sustainable MR for radiation oncology Amsterdam, the Netherlands – At the American Society for Radiation Oncology () 2025 Annual Meeting, (NYSE: PHG, AEX: PHIA), a global leader in health technolog...

Javier Esteban
  • Javier Esteban

INFORME SECTORIAL BANCOS ESPAÑA/EUROPA: EL MERCADO YA DESCUENTA RÉCORD...

El mercado ya descuenta récord de beneficios 2026. En los últimos seis meses el sector ha subido +17% (vs +9% IBEX y +4% ES 50) con una revisión de estimaciones a medio plazo de +11%.

 PRESS RELEASE

EssilorLuxottica: Essilor Stellest is the first and only FDA market au...

EssilorLuxottica: Essilor Stellest is the first and only FDA market authorized spectacle lens in the United States Essilor Stellest is the first and only FDA market authorized spectacle lens in the United States EssilorLuxottica’s lens is clinically proven to slow myopia progression in children1,2 Paris, France (25 September 2025) – EssilorLuxottica today announced the U.S. Food and Drug Administration (FDA) has granted market authorization for its Essilor Stellest lens using the De Novo pathway. This follows the product’s earlier recognition with the FDA granting designation as a Breakt...

 PRESS RELEASE

EssilorLuxottica: Essilor Stellest est le tout premier verre optique à...

EssilorLuxottica: Essilor Stellest est le tout premier verre optique à recevoir de la FDA une autorisation de mise sur le marché aux États-Unis Essilor Stellest est le tout premier verre optique à recevoir de la FDA une autorisation de mise sur le marché aux États-Unis L’efficacité du verre d'EssilorLuxottica pour ralentir la progression de la myopie infantile est cliniquement prouvée1,2 Paris, France (25 septembre, 2025) – EssilorLuxottica a annoncé aujourd'hui que la Food and Drug Administration (FDA) des États-Unis lui a accordé une autorisation de mise sur le marché pour son verre Ess...

 PRESS RELEASE

EssilorLuxottica: Essilor Stellest sono le prime e uniche lenti oftalm...

EssilorLuxottica: Essilor Stellest sono le prime e uniche lenti oftalmiche autorizzate alla vendita dall’FDA negli Stati Uniti Essilor Stellest sono le prime e uniche lenti oftalmiche autorizzate alla vendita dall’FDA negli Stati Uniti Studi clinici dimostrano l’efficacia delle lenti di EssilorLuxottica nel rallentare la progressione della miopia nei bambini1,2 Parigi, Francia (25 settembre 2025) – EssilorLuxottica annuncia di aver ottenuto l’autorizzazione dalla Food and Drug Administration (FDA) alla commercializzazione delle lenti Essilor Stellest grazie al percorso regolatorio De Nov...

 PRESS RELEASE

Philips joins Optum Healthcare’s network as a preferred provider in th...

Philips joins Optum Healthcare’s network as a preferred provider in the USA September 25, 2025 Philips’ ambulatory and diagnostic solutions and services are now available to 3.4 million Optum policyholders for enhanced outpatient cardiac monitoring Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has entered a national partnership in the USA with Optum Healthcare. The inclusion of Philips’ (MCOT) and Philips Extended Holter (ePatch) in the network is designed to enable earlier detection of cardiac conditions and timely cli...

Iberdrola S.A.: 1 director

A director at Iberdrola S.A. bought 5,183 shares at 15.628EUR and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

Louis Boujard ... (+3)
  • Louis Boujard
  • CFA
  • Philippe Ourpatian
Louis Boujard ... (+3)
  • Louis Boujard
  • CFA
  • Philippe Ourpatian
Research Department
  • Research Department

IBERIAN DAILY 25 SEPTEMBER (ANÁLISIS BANCO SABADELL)

NEWS SUMMARY: CAF, IBERDROLA, SANTANDER. Drivers lacking to hit new highs In a session without drivers, European stock markets were a mixed bag after Trump reaffirmed his support of NATO’s defence. In the STOXX 600, the best-performing sectors were cyclicals linked to raw materials like Basic Materials and Energy, but also the industrial subsector of Defence, whereas Construction and Financial Services ended with the biggest drops. On the macro side, in Germany the IFO worsened unexpectedly in ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch